Fig 1.
Patients who developed a censuring event during the follow up period contributed to the study until the date of the occurrence of the censoring event.
Table 1.
Preparation and administration of study medication.
Table 2.
Patient characteristics.
Fig 2.
Proportion of catheters free of thrombotic dysfunction.
Kaplan-Meier estimates with censoring at the time of the first thrombotic dysfunction. Population at risk during the 6 months follow up is indicated under the graph. Placebo (blue lines) and once weekly urokinase (red lines). P value of null hypothesis of no difference in survival by log-rank test = 0.01.
Table 3.
Primary and secondary efficacy outcomes.
Table 4.
Reasons for early study termination other than refractory thrombosis.
Table 5.
Evolution of hemodialysis adequacy parameters during the 6-month study period.
Table 6.
Costs of prophylactic and therapeutic catheter locks per patient during the 6-month study period 1.